Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 438 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: coagulation study Clear all
Completed Phase 3 Interventional Results available

BAY81-8973 Pediatric Safety and Efficacy Trial

NCT01311648
View directory record Official record
Conditions
Haemophilia A
Interventions
Recombinant Factor VIII (Kovaltry, BAY81-8973)
Biological
Lead sponsor
Bayer
Industry
Eligibility
0 Years to 12 Years · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma

NCT01176474
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
NY-ESO-1 157-165 (165V), Nivolumab, gp100:280-288 (288V), Montanide ISA 51 vegetable grade (VG), Ipilimumab, Apheresis Procedure
Biological · Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
16 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Prospective Biomarkers of Bone Metabolism in Hemophilia A

NCT02306694
View directory record Official record
Conditions
Hemophilia, Bone Disease
Interventions
Advate
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
16 Years to 85 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 1, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Determine the Inter/Intra Observer and Intra-subject Variability of Whole Blood Clotting Time Measurements

NCT02205827
View directory record Official record
Conditions
Healthy
Interventions
Single-arm
Other
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2Phase 3 Interventional

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901

NCT00157053
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic factor, recombinant, manufactured protein-free
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
10 Years and older · Male only
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
11
States / cities
Aurora, Colorado • Atlanta, Georgia • Peoria, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Safety and Efficacy of a 2,910 nm Fractional Ablative Fiber Laser (UltraClear®) for Improvements of Skin Laxity and Lifting of the Lower Face, Submental, and Neck Treatment Areas

NCT07759817
View directory record Official record
Conditions
Skin Laxity (Submental and Neck), Skin Lifting and Tightening
Interventions
2910 nm fiber laser (UltraClear®)
Device
Lead sponsor
FA Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Prospect, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

InFlux System for Nasal Breathing Improvement

NCT01960816
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Procedure: thermal coagulation of tissue in the nasal airway
Device
Lead sponsor
Aerin Medical
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts • Ocean Springs, Mississippi
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Outcomes Study of MTM in a Medicare ACO

NCT02875925
View directory record Official record
Conditions
Pain, Hypoglycemia
Interventions
MTM
Other
Lead sponsor
HealthEast Care System
Other
Eligibility
66 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 27, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study to Investigate if Early Atrial Fibrillation (AF) Diagnosis Reduces Risk of Events Like Stroke in the Real-World

NCT04276441
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Heart healthy Engagement Program with the Apple Watch Series 5 or later, Anti-Coagulation Adherence Module with the Apple Watch Series 5 or later
Device
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
65 Years and older
Enrollment
34,244 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jul 18, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women

NCT01252186
View directory record Official record
Conditions
Hemostasis, Oral Contraceptive
Interventions
91-day Levonorgestrel Oral Contraceptive, 28-day Levonorgestrel Oral Contraceptive, 28-day Desogestrel Oral Contraceptive
Drug
Lead sponsor
Teva Women's Health
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
265 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
21
States / cities
San Diego, California • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2015 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate the Effects of Repeated Periods of Modified Fasting to Support Healthy Natural Weight Management and Prevention of Weight Gain

NCT03372109
View directory record Official record
Conditions
Body Weight Changes
Interventions
Meal replacement shake, Multivitamin and mineral capsules, Fish oil with sesame lignans and olive extract softgel, Prebiotic Chewable tablet, Clove Extract and Maqui Berry extract capsule, .Whole Food Blend capsule, Turmeric extract capsule, European White Kidney Bean capsule, Saffron extract capsule, Ubiquinol with Fulvic acid complex softgel, Calcium with Hesperidin and gynostemma extract tablet, Multivitamin and mineral supplement
Dietary Supplement
Lead sponsor
Supplement Formulators, Inc.
Industry
Eligibility
21 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Coagulation Factor Changes Associated With Postpartum Hysterectomies

NCT00456547
View directory record Official record
Conditions
Obstetric Labor Complications, Hemorrhage, Complications; Cesarean Section
Interventions
Blood Draw
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 14, 2014 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Caloric Restriction and Protein Intake on Metabolism and Anabolic Sensitivity

NCT02945410
View directory record Official record
Conditions
Weight Loss, Starvation
Interventions
Caloric Restriction, Protein, Exercise, Calcium and Vitamin D, Maltodextrin
Other · Dietary Supplement
Lead sponsor
University of Nebraska Lincoln
Other
Eligibility
19 Years to 30 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Results available

Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution

NCT03326323
View directory record Official record
Conditions
Bleeding Reduction
Interventions
Acute Normovolemic Hemodilution
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 85 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting No phase listed Observational

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

NCT07071051
View directory record Official record
Conditions
Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
2 Years to 22 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Variability in the Measurement of WBCT Between Blood Drawn From Indwelling Catheters and Direct Venipuncture

NCT02207205
View directory record Official record
Conditions
Healthy
Interventions
Blood drawn from indwelling catheters versus direct venipuncture
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Apixaban in the Treatment of Heparin Induced Thrombocytopenia (HIT)

NCT03594045
View directory record Official record
Conditions
Heparin-induced Thrombocytopenia, Heparin-induced Thrombocytopenia and Thrombosis
Interventions
Apixaban
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational

Reference Range Study for the Quantra QStat System

NCT04219371
View directory record Official record
Conditions
Coagulation Disorder
Interventions
Quantra System
Diagnostic Test
Lead sponsor
HemoSonics LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Timeline
2020
U.S. locations
3
States / cities
Sandy Springs, Georgia • Raleigh, North Carolina • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19

NCT04634799
View directory record Official record
Conditions
Covid19
Interventions
TM5614, Placebo
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma

NCT00525447
View directory record Official record
Conditions
Multiple Myeloma
Interventions
SGN-40, lenalidomide, dexamethasone
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
9
States / cities
Denver, Colorado • Tampa, Florida • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2014 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Coagulation in Multiple Sclerosis

NCT01711255
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Bastyr University
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kenmore, Washington
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Regeneration of Pulp-Dentin Development in Teeth With Necrotic Pulps and Immature Roots

NCT01976065
View directory record Official record
Conditions
Pulp Necrosis, Regeneration
Interventions
Triple Antibiotic Paste, Standard Treatment
Drug · Other
Lead sponsor
Kenneth Hargreaves
Other
Eligibility
6 Years to 20 Years
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
4
States / cities
Loma Linda, California • Baltimore, Maryland • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Results available

Procurement of Leukapheresis Products From End Stage Liver Disease (ESLD) Patients for Immunological Studies

NCT02447926
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Leukapheresis
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 22, 2026, 5:25 AM EDT